Cargando…

RET Gene Fusions in Malignancies of the Thyroid and Other Tissues

Following the identification of the BCR-ABL1 (Breakpoint Cluster Region-ABelson murine Leukemia) fusion in chronic myelogenous leukemia, gene fusions generating chimeric oncoproteins have been recognized as common genomic structural variations in human malignancies. This is, in particular, a frequen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santoro, Massimo, Moccia, Marialuisa, Federico, Giorgia, Carlomagno, Francesca
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7230609/ https://www.ncbi.nlm.nih.gov/pubmed/32326537 http://dx.doi.org/10.3390/genes11040424

Ejemplares similares

Identification of Novel Small Molecule Inhibitors of Oncogenic RET Kinase
por: Moccia, Marialuisa, et al.
Publicado: (2015)

D898_E901 RET Deletion Is Oncogenic, Responds to Selpercatinib, and Treatment Resistance Can Arise Via RET-Independent Mechanisms
por: Porcelli, Tommaso, et al.
Publicado: (2023)

Targeted activity of the small molecule kinase inhibitor Pz-1 towards RET and TRK kinases
por: Moccia, Marialuisa, et al.
Publicado: (2021)

Bioisosteric Discovery of NPA101.3, a Second-Generation RET/VEGFR2 Inhibitor Optimized for Single-Agent Polypharmacology
por: Moccia, Marialuisa, et al.
Publicado: (2020)

Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours.
por: Santoro, M., et al.
Publicado: (1993)

Response to RET-Specific Therapy in RET Fusion-Positive Anaplastic Thyroid Carcinoma
por: Dias-Santagata, Dora, et al.
Publicado: (2020)

RET kinase inhibitors for RET-altered thyroid cancers
por: Vodopivec, Danica M., et al.
Publicado: (2022)

RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis
por: Bulanova Pekova, Barbora, et al.
Publicado: (2023)

RET Gene Abnormalities and Thyroid Disease: Who Should be Screened and When
por: Salehian, Behrouz, et al.
Publicado: (2013)

Durable Disease Control by RET Inhibitor Selpercatinib in a Heavily Pre-Treated RET Fusion-Positive Papillary Thyroid Cancer
por: Yokota, Tomoya
Publicado: (2022)

The Difference in Clinical Behavior of Gene Fusions Involving RET/PTC Fusions and THADA/IGF2BP3 Fusions in Thyroid Nodules
por: Tali, George, et al.
Publicado: (2023)

Systematic population-based identification of NTRK and RET fusion-positive thyroid cancers
por: Eszlinger, Markus, et al.
Publicado: (2021)

A RET::GRB2 fusion in pheochromocytoma defies the classic paradigm of RET oncogenic fusions
por: Estrada-Zuniga, Cynthia M., et al.
Publicado: (2022)

On the RET Rearrangements in Chernobyl-Related Thyroid Cancer
por: Jargin, Sergei V.
Publicado: (2012)

Proteogenomics analysis unveils a TFG-RET gene fusion and druggable targets in papillary thyroid carcinomas
por: Krishnan, Aswini, et al.
Publicado: (2020)

The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies
por: Solomon, Benjamin J., et al.
Publicado: (2020)

Highly sensitive droplet digital PCR for detection of RET fusion in papillary thyroid cancer
por: Chen, Mengke, et al.
Publicado: (2023)

The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis
por: Ke, Jun-yi, et al.
Publicado: (2023)

Molecular Basis of Medullary Thyroid Carcinoma: The Role of RET Polymorphisms
por: Ceolin, Lucieli, et al.
Publicado: (2011)

RET Fusion: Joining the Ranks of Targetable Molecular Drivers in NSCLC
por: Osta, Badi El, et al.
Publicado: (2020)

Catalog of 5′ fusion partners in RET+ NSCLC Circa 2020
por: Ou, Sai-Hong Ignatius, et al.
Publicado: (2020)

The RET gene encodes RET protein, which triggers intracellular signaling pathways for enteric neurogenesis, and RET mutation results in Hirschsprung's disease
por: Bhattarai, Chacchu, et al.
Publicado: (2022)

Responsiveness to immune checkpoint inhibitors versus other systemic therapies in RET-aberrant malignancies
por: Hegde, Aparna, et al.
Publicado: (2020)

Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers
por: Rosen, Ezra Y., et al.
Publicado: (2022)

Higher RET Gene Expression Levels Do Not Represent anAlternative RET Activation Mechanism in Medullary Thyroid Carcinoma
por: Mulè, Chiara, et al.
Publicado: (2021)

RET Fusion Genes in Korean Non-Small Cell Lung Cancer
por: Yoo, Seung Soo, et al.
Publicado: (2013)

Emerging oncogenic fusions other than ALK, ROS1, RET, and NTRK in NSCLC and the role of fusions as resistance mechanisms to targeted therapy
por: Suda, Kenichi, et al.
Publicado: (2020)

Lenvatinib and selpercatinib successfully treated RET fusion gene-positive papillary thyroid carcinoma cardiac metastases: a case report
por: Toda, Soji, et al.
Publicado: (2023)

Detection of RET oncogene activation in human papillary thyroid carcinomas by in situ hybridisation.
por: Fabien, N., et al.
Publicado: (1992)

Destabilizing RET in targeted treatment of thyroid cancers
por: Gild, M L, et al.
Publicado: (2015)

Precision oncology for RET-related tumors
por: Verrienti, Antonella, et al.
Publicado: (2022)

Selective RET inhibitors shift the treatment pattern of RET fusion-positive NSCLC and improve survival outcomes
por: Lu, Chang, et al.
Publicado: (2022)

Exceptional response to neoadjuvant targeted therapy with the selective RET inhibitor selpercatinib in RET-fusion-associated sarcoma
por: Schrenk, Karin G., et al.
Publicado: (2022)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

siRNA nanoformulation against the Ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma
por: de Martimprey, Henri, et al.
Publicado: (2008)

Molecular Basis and Natural History of Medullary Thyroid Cancer: It is (Almost) All in the RET
por: Sahakian, Nicolas, et al.
Publicado: (2023)

The clinical significance of RET gene fusion among Chinese patients with lung cancer
por: Xing, Puyuan, et al.
Publicado: (2020)

Neuroblastoma in a transgenic mouse carrying a metallothionein/ret fusion gene.
por: Iwamoto, T., et al.
Publicado: (1993)

Detecting ALK, ROS1 and RET Fusion Genes in Cell Block Samples()()
por: Zhao, Chao, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_n17cqeovu917av98e34ssk9dto